Lung cancer is one of the most lethal cancers globally, with China bearing a particularly significant burden. It remains a leading cause of cancer-related deaths, with over 700,000 fatalities annually. Despite considerable advances in cancer treatment, the vast majority of lung cancer cases in China are diagnosed at later stages, limiting the chances for curative intervention. This alarming situation has prompted the Chinese government and healthcare professionals to focus on early-stage detection, an effort largely centered around Low-Dose Computed Tomography (LDCT). This screening technique has emerged as a promising solution to detect lung cancer at an earlier, more treatable stage.
As of 2025, the China lung cancer screening market is projected to reach a value of approximately US$ 616.2 million, with expectations for it to expand rapidly over the next several years. By 2032, the market is forecasted to reach US$ 1,295.5 million, growing at a compound annual growth rate (CAGR) of 11.2%. The growth of this market is not only driven by the high incidence of lung cancer but also by government-backed initiatives aimed at making lung cancer screening more accessible and widespread.
Key Growth Drivers Behind Market Growth
The key drivers of growth in China’s lung cancer screening market are primarily related to government policies, technological advancements, and the growing awareness of lung cancer. Government initiatives, such as the National Cancer Screening Program (NCSP), have significantly boosted the adoption of LDCT screening, making it available to high-risk populations across the country. Moreover, collaborations between AI firms and hospitals are increasing the accuracy of screenings and helping reduce the burden on radiologists. These technological enhancements are contributing to a more efficient and widespread adoption of lung cancer screening methods.
Another critical factor in the market’s growth is the high incidence of non-small cell lung cancer (NSCLC), particularly adenocarcinoma, which is more common in non-smokers, particularly in urban areas. As the recognition of lung cancer as a public health priority continues to rise, more individuals are being screened, thereby increasing demand for screening services.
Leading Segment and Geographical Region
In terms of segmentation, LDCT is expected to be the dominant screening method, accounting for around 71.4% of the market share by 2025. This is due to its superior ability to detect early-stage lung cancer and its cost-effectiveness when compared to other methods such as chest X-rays. Within the market, the non-small cell lung cancer (NSCLC) segment will continue to dominate, as it represents the majority of new lung cancer cases in China.
Geographically, Shandong province is expected to experience significant growth within the lung cancer screening market. This is driven by high lung cancer incidence rates in the region, alongside government initiatives promoting LDCT screening. Additionally, provinces like Jiangsu and Sichuan are seeing increased uptake of screening programs, although there remains significant room for growth in rural areas where healthcare infrastructure and awareness are lacking.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35427
Key Highlights from the Report
➤ The China lung cancer screening market is expected to reach US$ 1,295.5 million by 2032, growing at a CAGR of 11.2%.
➤ Government-backed initiatives are driving the adoption of LDCT screening in high-risk populations.
➤ Shandong is projected to see steady growth due to high lung cancer incidence rates and a strong uptake of screening programs.
➤ LDCT scans are expected to dominate the market with a share of 71.4% in 2025 due to their effectiveness in early cancer detection.
➤ NSCLC remains the predominant cancer type in China, particularly adenocarcinoma, which is more prevalent among non-smokers.
➤ AI advancements in lung nodule detection are expected to boost screening accuracy and efficiency.
Market Segmentation
The China lung cancer screening market can be segmented based on various factors such as product type, cancer type, and diagnostic method. In terms of diagnostic methods, the market is divided into Low-Dose Spiral CT (LDCT) and chest X-rays. LDCT is expected to hold the largest market share due to its superior ability to detect early-stage lung cancers. Its higher sensitivity and cost-efficiency make it the gold standard for screening, particularly in high-risk populations. As of 2025, LDCT is expected to account for over 70% of the market share.
On the other hand, chest X-rays are likely to continue to play a role in screening, particularly for increasing awareness and familiarity with lung cancer. While less accurate than LDCT, chest X-rays remain an essential diagnostic tool, especially in rural or underserved areas. Economically, chest X-rays are more accessible and serve as a complementary tool to LDCT in large-scale population surveys.
Additionally, the market can be segmented by cancer type into Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). NSCLC is expected to dominate the market, with a projected share of over 80% in 2025. This is due to the increasing number of adenocarcinoma cases, which are frequently detected at early stages through LDCT scans. While SCLC is less common, it is expected to grow at a higher CAGR from 2025 to 2032 due to its rising prevalence in certain provinces and its relatively high association with smoking.
Regional Insights
Trends in Key Regions
Shandong: The province of Shandong is experiencing rapid growth in lung cancer screening due to the high lung cancer incidence and mortality rates. The adoption of LDCT screening in the province has been fueled by government initiatives and public awareness campaigns. Despite the progress, challenges in access and compliance persist, particularly in rural areas.
Sichuan: In Sichuan, the uptake of lung cancer screening is higher than in many other parts of the country, with over 95% of high-risk individuals having access to LDCT screening within 60 minutes. However, the province still faces significant spatial inequities, particularly in the rural western regions, where access to healthcare is limited.
Jiangsu: Jiangsu province is one of the more developed areas in China and has seen a higher uptake of lung cancer screening compared to rural provinces. The province benefits from improved healthcare infrastructure and government backing for LDCT screening, though further focus on female populations and high-risk areas is needed to maintain or enhance screening rates.
Market Drivers
Several factors are driving the growth of the China lung cancer screening market. Government initiatives play a pivotal role, particularly the incorporation of lung cancer in the National Cancer Screening Program (NCSP). These initiatives make LDCT screening more accessible, especially for high-risk populations. Additionally, technological innovations, such as the integration of artificial intelligence (AI) into screening processes, are improving the accuracy of early-stage cancer detection, which is critical for reducing mortality rates.
As China’s population ages, the number of individuals at high risk for lung cancer continues to rise. Furthermore, lifestyle factors such as air pollution and smoking contribute to the high incidence of lung cancer, making early detection even more vital. The growing recognition of lung cancer as a public health priority also encourages more individuals to undergo regular screenings.
Market Restraints
Despite the positive market outlook, several challenges could limit the full potential of the China lung cancer screening market. Low uptake rates remain a significant issue, even with free screening programs available. Issues such as out-of-pocket costs for follow-ups, distrust in healthcare institutions, and logistical barriers in rural areas hinder participation.
Another constraint is the high false-positive rate associated with LDCT screening, which can lead to unnecessary anxiety, additional imaging, invasive procedures, and financial burdens on patients. This may discourage individuals from participating in screening programs, despite their potential life-saving benefits.
Market Opportunities
The incorporation of AI and other advanced technologies presents significant opportunities for improving lung cancer screening outcomes in China. AI-driven image analysis has already demonstrated impressive results, with improved detection rates for early-stage lung cancers and a reduction in radiologist workload. Continued investment in AI research and development can further enhance screening accuracy and make the process more efficient.
Additionally, as the Chinese government continues to support screening programs through funding and policy development, there is an opportunity for private companies to expand their presence in the market by providing affordable, accessible, and effective screening solutions.
Reasons to Buy the Report
✔ Gain insights into government policies driving the growth of the lung cancer screening market in China.
✔ Understand the key players and competitive landscape within the market.
✔ Access detailed forecasts for the lung cancer screening market size and growth projections.
✔ Identify key regional trends and opportunities for expansion.
✔ Learn about technological innovations and AI integration in the lung cancer screening process.
Frequently Asked Questions (FAQs)
- How Big is the China Lung Cancer Screening Market?
- Who are the Key Players in the China Lung Cancer Screening Market?
- What is the Projected Growth Rate of the China Lung Cancer Screening Market?
- What is the Market Forecast for China Lung Cancer Screening by 2032?
- Which Region is Estimated to Dominate the Lung Cancer Screening Market through the Forecast Period?
Company Insights
Key Players
✦ Biodesix
✦ GE HealthCare
✦ DELFI Diagnostics, Inc.
✦ Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
✦ CANON MEDICAL SYSTEMS CORPORATION
✦ Siemens Healthineers AG
✦ Medtronic plc
✦ Koninklijke Philips N.V.
✦ Freenome Holdings, Inc.
✦ Shanghai United Imaging Healthcare Co., LTD.
Recent Developments
In April 2025, researchers at the Guangzhou Institute of Respiratory Disease discovered that lung cancer screening with LDCT was equally effective in detecting cancers in non-smokers as it was in smokers.
In January 2025, Sichuan University conducted a study assessing the awareness levels of lung cancer in urban residents, revealing that only 23.88% of participants had sufficient awareness about the disease.
The China lung cancer screening market is evolving rapidly, supported by government efforts, technological advancements, and increasing awareness of the disease. The ongoing challenges and opportunities in improving screening uptake will shape the future of the market, offering significant potential for both public health improvement and business expansion.
Read More Related Reports:
Polymerase Chain Reaction Market
Anti Vascular Endothelial Growth Factor Therapeutics Market
